Biogen Idec and Isis Pharmaceuticals To Collaborate On Antisense Programs - - BioPharm International

ADVERTISEMENT

Biogen Idec and Isis Pharmaceuticals To Collaborate On Antisense Programs



Biogen Idec and Isis Pharmaceuticals announced that they have entered into a global collaboration agreement to discover and develop antisense drugs against three undisclosed targets to treat neurological or neuromuscular disorders. Isis will be responsible for development of the drugs through the completion of the initial Phase 2 clinical trial, with Biogen Idec providing advice and assistance on research, clinical trial design and conduct, and regulatory strategy for each program. Biogen Idec has the option to license a drug from each of the three programs through the completion of Phase 2 trials, and if it exercises its option, Biogen Idec will be responsible for global development, regulatory, and commercialization.

In the accompanying press release, Richard Brudnick, vice-president and co-head of business development at Biogen Idec said, "This will be our third collaboration with Isis, which is reflective of our respect for them as a partner and as a leader in antisense technology. By combining Isis' knowledge with Biogen Idec's expertise as a leader in neurology, we believe this latest discovery collaboration holds great potential for finding novel approaches to treating neurologic diseases."

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here